NASDAQ:SWAV

Shockwave Medical (SWAV) Stock Price, News & Analysis

$328.54
-0.06 (-0.02%)
(As of 04/23/2024 ET)
Today's Range
$328.40
$329.28
50-Day Range
$230.90
$329.64
52-Week Range
$157.00
$331.58
Volume
889,375 shs
Average Volume
2.15 million shs
Market Capitalization
$12.29 billion
P/E Ratio
84.89
Dividend Yield
N/A
Price Target
$309.11

Shockwave Medical MarketRank™ Stock Analysis

Analyst Rating
Hold
2.09 Rating Score
Upside/​Downside
5.9% Downside
$309.11 Price Target
Short Interest
Bearish
5.43% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.55
Upright™ Environmental Score
News Sentiment
0.81mentions of Shockwave Medical in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$23.76 M Sold Last Quarter
Proj. Earnings Growth
26.11%
From $4.94 to $6.23 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.38 out of 5 stars

Medical Sector

110th out of 909 stocks

Surgical & Medical Instruments Industry

18th out of 96 stocks

SWAV stock logo

About Shockwave Medical Stock (NASDAQ:SWAV)

Shockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California.

SWAV Stock Price History

SWAV Stock News Headlines

MarketBeat Week in Review – 4/8 - 4/12 (SWAV)
The latest inflation readings moved stocks lower as investors reconsidered what higher-for-longer interest rates mean for corporate earnings and stock valuation
Will the Shockwave Medical Deal Be the Jolt JNJ Stock Needs?
On April 5, 2024, Johnson & Johnson NYSE: JNJ announced its intent to acquire Shockwave Medical Inc. NASDAQ: SWAV for $13.1 billion. Under the terms of the proposed deal, JNJ will pay $335 per share, which is a 4.75% premium compared to Shockwave's closing price on April 4, 2024.
Elon Musk’s Controversial New Project: “Apollo”
Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...
Will the Shockwave Medical Deal Be the Jolt JNJ Stock Needs? (SWAV)
Johnson & Johnson's proposed acquisition of Shockwave Medical may be the jolt that JNJ stock needs to break out of a year-long downtrend
Newmont, Shockwave Medical rise; John Bean fall, Friday, 4/4/2024
Stocks that are trading heavily or have substantial price changes on Friday: Newmont, Shockwave Medical rise; John Bean fall
Elon Musk’s Controversial New Project: “Apollo”
Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...
J&J CFO on Q1 Earnings, Forecast and Product Pipeline
See More Headlines
Receive SWAV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Shockwave Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
4/24/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:SWAV
Fax
N/A
Employees
1,468
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$309.11
High Stock Price Target
$368.00
Low Stock Price Target
$210.00
Potential Upside/Downside
-5.9%
Consensus Rating
Hold
Rating Score (0-4)
2.09
Research Coverage
11 Analysts

Profitability

Net Income
$147.28 million
Pretax Margin
23.87%

Debt

Sales & Book Value

Annual Sales
$730.23 million
Cash Flow
$4.31 per share
Book Value
$18.12 per share

Miscellaneous

Free Float
36,126,000
Market Cap
$12.29 billion
Optionable
Optionable
Beta
0.92
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives


SWAV Stock Analysis - Frequently Asked Questions

Should I buy or sell Shockwave Medical stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Shockwave Medical in the last twelve months. There are currently 10 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" SWAV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SWAV, but not buy additional shares or sell existing shares.
View SWAV analyst ratings
or view top-rated stocks.

What is Shockwave Medical's stock price target for 2024?

11 brokerages have issued 1 year target prices for Shockwave Medical's stock. Their SWAV share price targets range from $210.00 to $368.00. On average, they anticipate the company's stock price to reach $309.11 in the next twelve months. This suggests that the stock has a possible downside of 5.9%.
View analysts price targets for SWAV
or view top-rated stocks among Wall Street analysts.

How have SWAV shares performed in 2024?

Shockwave Medical's stock was trading at $190.56 at the beginning of the year. Since then, SWAV stock has increased by 72.4% and is now trading at $328.54.
View the best growth stocks for 2024 here
.

When is Shockwave Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our SWAV earnings forecast
.

How were Shockwave Medical's earnings last quarter?

Shockwave Medical, Inc. (NASDAQ:SWAV) released its earnings results on Thursday, February, 15th. The company reported $1.16 EPS for the quarter, beating the consensus estimate of $0.92 by $0.24. The firm had revenue of $202.98 million for the quarter, compared to the consensus estimate of $199.43 million. Shockwave Medical had a trailing twelve-month return on equity of 23.97% and a net margin of 20.17%. Shockwave Medical's revenue was up 41.0% compared to the same quarter last year. During the same period in the previous year, the company earned $3.71 earnings per share.

What guidance has Shockwave Medical issued on next quarter's earnings?

Shockwave Medical issued an update on its FY 2024 earnings guidance on Friday, February, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $910.0 million-$930.0 million, compared to the consensus revenue estimate of $918.9 million.

What is Doug Godshall's approval rating as Shockwave Medical's CEO?

8 employees have rated Shockwave Medical Chief Executive Officer Doug Godshall on Glassdoor.com. Doug Godshall has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Shockwave Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Shockwave Medical investors own include NVIDIA (NVDA), Walt Disney (DIS), Block (SQ), Trade Desk (TTD), Salesforce (CRM), Roku (ROKU), PayPal (PYPL), DexCom (DXCM), Alibaba Group (BABA) and Okta (OKTA).

When did Shockwave Medical IPO?

Shockwave Medical (SWAV) raised $75 million in an IPO on Thursday, March 7th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

Who are Shockwave Medical's major shareholders?

Shockwave Medical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (1.38%), Artemis Investment Management LLP (0.23%), Amalgamated Bank (0.05%), Raymond James Financial Services Advisors Inc. (0.05%), Gradient Investments LLC (0.05%) and AMI Asset Management Corp (0.05%). Insiders that own company stock include Antoine Papiernik, Colin Cahill, Dan Puckett, Douglas Evan Godshall, Frank T Watkins, Frank T Watkins, Frederic H Moll, Isaac Zacharias, Kurt F Gallo, Laura Francis, Maria Sainz, Sara Toyloy and Trinh Phung.
View institutional ownership trends
.

How do I buy shares of Shockwave Medical?

Shares of SWAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SWAV) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners